聚乙二醇4000联合莫沙比利治疗老年功能性便秘疗效分析

目的:评价聚乙二醇4000联合莫沙比利治疗老年功能性便秘的疗效。方法:76例老年功能性便秘患者被随机分为两组。治疗组45例,口服聚乙二醇400010g,每日2次,莫沙比利5mg,每日3次;对照组31例,口服聚乙二醇400010g,每日2次,疗程4周。分别于第2周和第4周记录患者治疗情况,并观察药物不良反应。结果:治疗2周后,治疗组和对照组粪便性状恢复正常者为68.9%vs63.3%;4周时治疗组和对照组粪便性状恢复正常为77.8%vs63.3%,组间比较差异均无统计学意义。治疗2周时治疗组和对照组的总有效率为91.1%vs86.7%(P=0.225),4周时总有效率为95.6% vs 90.0%(P=0.182);但2周和4周显效率比较差异有统计学意义(68.9% vs 46.7%,P=0.046;84.4% vs63.3%,P=0.001)。治疗期间,除对照组1例患者因自觉不适退出,两组均未发生明显不良反应。结论:聚乙二醇4000联合莫沙比利治疗老年功能性便秘安全、有效,其疗效明显优于单纯使用聚乙二醇4000。

Therapeutic Effect of PEG4000 Combined With Mosapride on Elderly Functional Constipations

Objective:To evaluate the efficacy of PEG4000 combined with Mosapride for the treatment of elderly functional constipations.Methods:76 older patients with functional constipation were included and allocated to therapeutic group(n=45) or the control group(n=31).All patients received PEG4000 10mg,twice a day;Therapeutic group also received Mosapride 5mg,three times per day.Therapeutic outcomes and side-effects were evaluated at fellow-up of 2 weeks and 4 weeks respectively.Results:Although there were no signi...